IgG-mediated down-regulation of IgE bound to mast cells: A potential novel mechanism of allergen-specific desensitization

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 69, Issue 3, 2014, Pages 338-347

  Uermosi C ^a   Zabel, F ^b   Manolova, V ^a   Bauer, M ^c   Beerli, R R ^c   Senti, G ^b   Kundig T M ^b   Saudan, P ^a   Bachmann, M F ^b,d  

^a CYTOS BIOTECHNOLOGY AG   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Intercell AG   (Switzerland)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

basic mechanisms; IgE; immunotherapy and tolerance induction; mast cells; prevention

Indexed keywords

BASIC MECHANISMS; IGE; IMMUNOTHERAPY AND TOLERANCE INDUCTION; MAST CELLS; PREVENTION;

ALLERGENS; ANIMALS; ANTIBODY SPECIFICITY; DESENSITIZATION, IMMUNOLOGIC; DOWN-REGULATION; EPITOPES; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOMODULATION; MAST CELLS; MICE; MICE, KNOCKOUT; RECEPTORS, IGG;

EID: 84894265496     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12327     Document Type: Article

References (34)

1. Gould HJ, Sutton BJ,. IgE in allergy and asthma today. Nat Rev Immunol 2008; 8: 205-217.
2. Holgate ST,. The epidemic of allergy and asthma. Nature 1999; 402 (Suppl): B2-B4.
3. Upton MN, McConnachie A, McSharry C, Hart CL, Smith GD, Gillis CR, et al. Intergenerational 20 year trends in the prevalence of asthma and hay fever in adults: the Midspan family study surveys of parents and offspring. BMJ 2000; 321: 88-92.
4. Haba S, Ovary Z, Nisonoff A,. Clearance of IgE from serum of normal and hybridoma-bearing mice. J Immunol 1985; 134: 3291-3297.
5. MacGlashan D Jr,. IgE receptor and signal transduction in mast cells and basophils. Curr Opin Immunol 2008; 20: 717-723.
6. Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M,. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu Rev Immunol 2005; 23: 749-786.
7. Triggiani M, Oriente A, Seeds MC, Bass DA, Marone G, Chilton FH,. Metabolism of lipid mediators in human basophils and mast cells. Chem Immunol 1995; 61: 135-147.
8. Galli SJ, Gordon JR, Wershil BK,. Cytokine production by mast cells and basophils. Curr Opin Immunol 1991; 3: 865-872.
9. Hedlin G, Graff-Lonnevig V, Heilborn H, Lilja G, Norrlind K, Pegelow K, et al. Immunotherapy with cat- and dog-dander extracts. V. Effects of 3 years of treatment. J Allergy Clin Immunol 1991; 87: 955-964.
10. Hedlin G, Graff-Lonnevig V, Heilborn H, Lilja G, Norrlind K, Pegelow KO, et al. Immunotherapy with cat- and dog-dander extracts. II. In vivo and in vitro immunologic effects observed in a 1-year double-blind placebo study. J Allergy Clin Immunol 1986; 77: 488-496.
11. Bousquet J, Lockey R, Malling HJ,. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998; 1: 558-562.
12. Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003; 33: 1205-1214.
13. Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth MT, Valent P, et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci USA 2004; 101 (Suppl 2): 14677-14682.
14. Schmitz N, Dietmeier K, Bauer M, Maudrich M, Utzinger S, Muntwiler S, et al. Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy. J Exp Med 2009; 206: 1941-1955.
15. Lichtenstein LM, Holtzman NA, Burnett LS,. A quantitative in vitro study of the chromatographic distribution and immunoglobulin characteristics of human blocking antibody. J Immunol 1968; 101: 317-324.
16. Uermösi C, Beerli RR, Bauer M, Manolova V, Dietmeier K, Buser RB, et al. Mechanisms of allergen-specific desensitization. J Allergy Clin Immunol 2010; 126: 375-383.
17. Daëron M, Latour S, Malbec O, Espinosa E, Pina P, Pasmans S, et al. Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J Clin Invest 1995; 95: 577-585.
18. Zhang K, Kepley CL, Terada T, Zhu D, Perez H, Saxon A,. Inhibition of allergen-specific IgE reactivity by a human Ig Fcgamma-Fcepsilon bifunctional fusion protein. J Allergy Clin Immunol 2004; 114: 321-327.
19. Zhu D, Kepley CL, Zhang K, Terada T, Yamada T, Saxon A,. A chimeric human-cat fusion protein blocks cat-induced allergy. Nat Med 2005; 11: 446-449.
20. Daëron M, Latour S, Malbec O, Espinosa E, Pina P, Pasmans S,. The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fc gamma RIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity 1995; 3: 635-646.
21. Malbec O, Fong DC, Turner M, Tybulewicz VL, Cambier JC, Fridman WH, et al. Fc epsilon receptor I-associated lyn-dependent phosphorylation of Fc gamma receptor IIB during negative regulation of mast cell activation. J Immunol 1998; 160: 1647-1658.
22. Ono M, Bolland S, Tempst P, Ravetch JV,. Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc(gamma)RIIB. Nature 1996; 383: 263-266.
23. Wilson BS, Pfeiffer JR, Oliver JM,. Observing FcepsilonRI signaling from the inside of the mast cell membrane. J Cell Biol 2000; 149: 1131-1142.
24. Beerli RR, Bauer M, Buser RB, Gwerder M, Muntwiler S, Maurer P, et al. Isolation of human monoclonal antibodies by mammalian cell display. Proc Natl Acad Sci USA 2008; 105: 14336-14341.
25. Katz HR, Arm JP, Benson AC, Austen KF,. Maturation-related changes in the expression of Fc gamma RII and Fc gamma RIII on mouse mast cells derived in vitro and in vivo. J Immunol 1990; 145: 3412-3417.
26. Golden DB, Meyers DA, Kagey-Sobotka A, Valentine MD, Lichtenstein LM,. Clinical relevance of the venom-specific immunoglobulin G antibody level during immunotherapy. J Allergy Clin Immunol 1982; 69: 489-493.
27. Muller U, Helbling A, Bischof M,. Predictive value of venom-specific IgE, IgG and IgG subclass antibodies in patients on immunotherapy with honey bee venom. Allergy 1989; 44: 412-418.
28. van Neerven RJ, Knol EF, Ejrnaes A, Würtzen PA,. IgE-mediated allergen presentation and blocking antibodies: regulation of T-cell activation in allergy. Int Arch Allergy Immunol 2006; 141: 119-129.
29. Wachholz PA, Durham SR,. Mechanisms of immunotherapy: IgG revisited. Curr Opin Allergy Clin Immunol 2004; 4: 313-318.
30. Larche M, Akdis CA, Valenta R,. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006; 6: 761-771.
31. Sellge G, Laffer S, Mierke C, Vrtala S, Hoffmann MW, Klempnauer J, et al. Development of an in vitro system for the study of allergens and allergen-specific immunoglobulin E and immunoglobulin G: fcepsilon receptor I supercross-linking is a possible new mechanism of immunoglobulin G-dependent enhancement of type I allergic reactions. Clin Exp Allergy 2005; 35: 774-781.
32. Molfetta R, Gasparrini F, Santoni A, Paolini R,. Ubiquitination and endocytosis of the high affinity receptor for IgE. Mol Immunol 2010; 47: 2427-2434.
33. Wilson BS, Pfeiffer JR, Oliver JM,. FcepsilonRI signaling observed from the inside of the mast cell membrane. Mol Immunol 2002; 38: 1259-1268.
34. Ejrnaes AM, Bodtger U, Larsen JN, Svenson M,. The blocking activity of birch pollen-specific immunotherapy-induced IgG4 is not qualitatively superior to that of other IgG subclasses. Mol Immunol 2004; 41: 471-478.